Wang Yuqin, Chang Lele, He Haixin, Zhang Xuemei, Liu Jing, Zang Lele, Li Li, Liu Tongyu, Xu Qin
Departments of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, Fujian, China.
Fujian Medical University, Fuzhou, 350014, Fujian, China.
Discov Oncol. 2025 Apr 17;16(1):545. doi: 10.1007/s12672-025-02205-y.
The COVID-19 pandemic has significantly impacted cancer diagnosis, treatment, and prognosis; however, its effects on ovarian cancer remain unclear.
This multicenter retrospective study utilized the Surveillance, Epidemiology, and End Results database to compare changes in the diagnosis, treatment, prognosis, and risk factors among ovarian cancer patients pre- and post-COVID-19 pandemic. Patients diagnosed before the pandemic (pre-COVID-19 group) and those diagnosed during the pandemic (post-COVID-19 group) were matched through 1:1 propensity score matching. Kaplan-Meier analysis compared cancer-specific survival (CSS) and overall survival (OS). Factors associated with survival were identified by the Cox proportional hazards model, while a competing risks model was used to determine factors associated with cancer-specific death.
A total of 9,112 ovarian cancer patients were included in the study, with 4,536 diagnosed before COVID-19 and 4576 diagnosed during COVID-19. The results showed that the post-COVID-19 group presented at a more advanced stage had lower tissue differentiation, experienced more delayed treatments, and received fewer surgical interventions. Although there was no significant difference in survival between the pre-COVID-19 group and the post-COVID-19 group, patients with delayed treatment had a worse prognosis than those without delayed treatment. Additionally, we identified independent factors associated with survival outcomes, including age, tumor grade, clinical stage, pathological stage, specific histology, treatment delays, surgical intervention, and systemic therapy.
The survival outcomes of the pre-COVID-19 group and the post-COVID-19 group were relatively consistent, likely due to the short follow-up. Future research is necessary to continue monitoring the outcomes of patients in the post-COVID-19 group to determine its long-term impact.
2019冠状病毒病（COVID-19）大流行对癌症的诊断、治疗和预后产生了重大影响；然而，其对卵巢癌的影响仍不清楚。
这项多中心回顾性研究利用监测、流行病学和最终结果数据库，比较COVID-19大流行前后卵巢癌患者在诊断、治疗、预后和风险因素方面的变化。大流行前诊断的患者（COVID-19前组）和大流行期间诊断的患者（COVID-19后组）通过1:1倾向评分匹配进行配对。采用Kaplan-Meier分析比较癌症特异性生存（CSS）和总生存（OS）。通过Cox比例风险模型确定与生存相关的因素，同时使用竞争风险模型确定与癌症特异性死亡相关的因素。
该研究共纳入9112例卵巢癌患者，其中4536例在COVID-19之前被诊断，4576例在COVID-19期间被诊断。结果显示，COVID-19后组患者就诊时分期更晚，组织分化程度更低，治疗延迟更多，接受手术干预更少。虽然COVID-19前组和COVID-19后组在生存率上没有显著差异，但治疗延迟的患者预后比未延迟治疗的患者更差。此外，我们确定了与生存结果相关的独立因素，包括年龄、肿瘤分级、临床分期、病理分期、特定组织学、治疗延迟、手术干预和全身治疗。
COVID-19前组和COVID-19后组的生存结果相对一致，可能是由于随访时间较短。有必要进行进一步研究，继续监测COVID-19后组患者的结局，以确定其长期影响。
